BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/27/2022 4:55:05 AM | Browse: 152 | Download: 342
 |
Received |
|
2022-05-31 15:09 |
|
Peer-Review Started |
|
2022-05-31 15:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-07-14 08:24 |
|
Revised |
|
2022-08-01 15:23 |
|
Second Decision |
|
2022-09-20 03:25 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-09-21 00:15 |
|
Articles in Press |
|
2022-09-21 00:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-09-18 09:51 |
|
Typeset the Manuscript |
|
2022-10-18 07:06 |
|
Publish the Manuscript Online |
|
2022-10-27 04:55 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pediatrics |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tong-Tong Cao, Li Chen, Xiao-Fang Zhen, Gao-Jie Zhao, Hui-Fang Zhang and Yan Hu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Capital Health Research and Development of Special |
No. CH2018-2-2092 |
|
| Corresponding Author |
Yan Hu, MD, PhD, Director, Doctor, Department of Traditional Chinese Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nanlishi Road, Beijing 100045, China. huyan13370115073@163.com |
| Key Words |
Lupus nephritis; Traditional Chinese medicine; Dan Bai Xiao Formula; Effective; Safe |
| Core Tip |
Lupus nephritis (LN) is the most common and serious complication of systemic lupus erythematosus. Glucocorticoids (GCs) and immunosuppressants were considered routine treatments for patients with LN. However, there is a widespread consensus regarding the toxicity of immunosuppressive agents and the necessity of preventing children from taking these medications over an extended period. Accordingly, there is an increasing need for holistic and optimal therapy that results in a higher rate of remission and fewer side effects. Our study suggests that Dan Bai Xiao Formula (DBXF) treatment is effective and safe as a supplementary therapy for LN; moreover, this treatment is superior to routine GC and cyclophosphamide therapies. DBXF containing combination treatment may lead to faster proteinuria and hematuria resolution, smoother GC reduction, fewer methylprednisolone pulses, and fewer adverse events. |
| Publish Date |
2022-10-27 04:55 |
| Citation |
Cao TT, Chen L, Zhen XF, Zhao GJ, Zhang HF, Hu Y. Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study. World J Clin Cases 2022; 10(31): 11391-11402 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i31/11391.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i31.11391 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
